Express News | Medicinova Chief Business Officer David H. Crean, Ph.d. Assumes Communications Role Overseeing Investor Engagement and Public Relations

BreakingsJun 20 18:00

Express News | Medicinova has received a new patent license notification for Mn-166 (ibudilast) for the prevention of various solid tumor metastases.

BreakingsJun 5 18:05

Express News | Medicinova Receives Notice of Allowance for New Patent Covering Mn-166 (Ibudilast) for the Prevention of Metastasis of Various Solid Cancer

BreakingsJun 5 18:04

MediciNova Presents New Data And Results Of Phase 1b/2a Clinical Trial Of MN-166 At ASCO Meeting

The highlights of presentation are as follows:The primary endpoints were safety and tolerability of MN-166 and TMZ combination treatment and the efficacy of combination treatment.The combination of Te

BenzingaJun 3 18:03

The combination of Tmz and Mn-166 is safe and well-tolerated, according to MediciNova company.

The combination of Tmz and Mn-166 is safe and well-tolerated, according to MediciNova company.

Zhitong FinanceJun 3 18:02

Medicinova announced at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting the phase 1B/2a clinical trial data of Mn-166 (ibudilast) for patients with glioblastoma in the United States.

Medicinova announced the phase 1B/2a clinical trial data of Mn-166 (ibudilast) for glioblastoma patients at the American Society of Clinical Oncology (ASCO) Annual Meeting in the United States in 2024.

Zhitong FinanceJun 3 18:00